ALK inhibitors are a class of targeted therapy drugs designed to specifically inhibit the activity of the abnormal ALK protein. Some of the FDA-approved ALK inhibitors include crizotinib, ceritinib, alectinib, and brigatinib. These drugs have shown significant effectiveness in treating cancers with ALK alterations, particularly NSCLC.
